Programme

Sunday, 15.09.2013

09:00-11:00 Set-up of exhibition

11:00 Welcome coffee, tea or soft drinks for the participants are available

11:00 Registration open

13:00-13:15 Welcome Addresses

Session I – International Activities, Disease Models & Human-on-a-chip

Chairs: Mardas Daneshian (DE) & Horst Spielmann (DE)

13:15-13:35 Hajime Kojima, National Institute of Health Sciences, JP-Tokyo
Japanese project “ARCH-Tox” for the future chemicals management policy: research and development of in vitro and in vivo assays for internationally leading hazard assessment and test methods

13:35-13:55 Horst Spielmann, Freie Universität Berlin, DE-Berlin
Peer review panel evaluation of the ROS Photosafety Assay

13:55-14:15 Mario Fabri, University of Cologne, DE-Cologne
Vitamin D-dependent antimicrobial pathways in human macrophages

14:15-14:35 Günther Weindl, Freie Universität Berlin, DE-Berlin
Increased cutaneous absorption reflects impaired barrier function of reconstructed skin models mimicking keratinisation disorders

14:35-14:55 Eva-Maria Materne, TU Berlin, DE-Berlin
A multi-organ-chip platform for long-term maintenance and substance testing of human tissue co-culture

14:55-15:15 Dmitry Sakharov, Scientific Research Centre Bioclinicum, RU-Moscow
A dynamic multi-organ-chip containing enterocytes and hepatocytes for the absorption of orally administered drugs prediction and substance toxicity testing

15:15-16:30 Poster session I + coffee break and exhibition
Chairs: Eleonore Haltner-Ukomadu (DE) & Tuula Heinonen (SF)

16:30-17:00 Horst Spielmann, Freie Universität Berlin, DE-Berlin
Willi Halle Memorial Lecture

Session II – 3Rs go 3D

Chairs: Helena Kandarova (SK) & Günter Weindl

17:00-17:30 Ellen Fritsche, Leibniz Research Institute of Environmental Medicine, DE-Düsseldorf
Human Neural Progenitor Cell (hNPC) Aging is mimicked by 3D Cultures in vitro: an ‘Adverse Outcome Pathway’ gains importance at susceptible life stages

17:30-17:45 Jens Kelm, InSphero AG, CH-Zürich
3-dimensional organotypic in vitro model systems for liver, cardiac and neuro safety assessment

17:45-18:00 Silvia Angeloni, CSEM SA, CH-Neuchâtel
Blood-brain tumor and air-blood tissue barrier: two examples of how BioMEMS can improve the relevance of co-cultured in-vitro models of biological barriers

18:00-18:15 Frederique van Acker, TNO Triskelion, NL-Zeist
Cerium oxide nanoparticles air exposure: a comparison study using a human 3D airway model, A549 and BEAS-2B cell lines

18:15-18:30 Nicky Slawny, 3D Biomatrix, Inc., US-Ann Arbor
3D spheroid cell cultures as models in drug discovery

18:30-18:45 Martha Liley. CSEM SA, CH-Neuchâtel
Towards replacing in vivo tests of dental and orthopedic implants

19:15-20:45 Annual general assembly of EUSAAT

Monday, 16.09.2013 – special day

( = session III of the 18th European Congress on Alternatives to Animal Testing)

ESNATS CONFERENCE – Preliminary Programme

“Use of Human Embryonic Stem Cells for Novel Toxicity Testing
Approaches”

09:00-09:10 Horst Spielmann, President of EUSAAT, Freie Universitaet Berlin, DE-Berlin
Opening address

09:10-09:20 Jürgen Hescheler, Coordinator of ESNATS, University of Cologne, DE-Cologne
Overview of the ESNATS project

09:20-10:00 Marcel Leist, University of Konstanz, DE-Konstanz
The ESNATS hESC-based toxicity test battery

10:00-10:40 Jan Hengstler, IFADO, DE-Dortmund
The ESNATS hESC-based toxicity biomarker identification study

10:40-11:00 Jan Hengstler, IFADO, DE-Dortmund
Hepatocyte in vitro systems to study metabolism: stem cell derived hepatocytes as an alternative to primary hepatocytes

11:00-11:15 Coffee break

11:15-11:30 Joery de Kock, Vrije Universiteit Brussels, BE-Brussels
hSKP-derived hepatocytes for toxicity testing

11:30-11:50 Sieto Bosgra, TNO, NL-Utrecht
In vitro-in vivo extrapolation of prenatal (neuro)toxicity assay data by PBPK modeling

11:50-12:10 Agapios Sachinidis, University of Cologne, DE-Cologne
Identification of thalidomide-specific transcriptomics and proteomics signatures during differentiation of human embryonic stem cells

12:10-12:30 Karl-Heinz Krause, University of Geneva, CH-Geneva
Pluripotent stem cell-derived engineered neural tissues: what’s new?

12:30-13:45 Lunch and posters

13:45-14:30 First panel discussion (chair: Thomas Hartung, CAAT, US Baltimore)
How can the ESNATS data be used to define mechanisms of action and/or AOPs

14:30-15:00 Aldert Piersma, RIVM, NL-Bilthoven
Enhancing the readout of the embryonic stem cell test with molecular approaches

15:00-15:30 Ellen Fritsche, Leibniz Research Institute for Environmental Medicine, DE-Duesseldorf
Signaling pathways in human neural assays (title to be confirmed)

15:30-16:00 Robert Kavlock, US Environmental Protection Agency, US-Washington
Transforming the Conduct of Toxicology in the US: the Tox21 Program

16:00-16:30 Coffee break and posters

16:30-17:00 Thomas Knudsen, US Environmental Protection Agency, US-Research Triangle Park
Predictive models and computational embryology

17:00-17:30 Beatriz Silva-Lima, EPAA stem cell group, BE-Brussels
EPAA calls for a “Stem Cells in Safety Testing” forum to keep fluent communication

17:30-18:00 Jos Kleinjans, University of Maastricht, NL-Maastricht
Data infrastructure for chemical safety

18:00-18:45 Second panel discussion (chair: Michael Schwarz, University of Tuebingen, DE-Tuebingen)
How can the ESNATS assays be applicable in companies/regulatory toxicology and what are necessary future developments

18:45-20:00 Continued discussion and poster session

20:00 Dinner and social evening (at the congress venue)
ESNATS & EUSAAT welcome you!

Tuesday, 17.09.2013

Session IV – EU Dir 2010/63 & Ethical & legal Aspects

Chairs: Susanna Louhimies (BE) & Ursula Sauer (DE)

09:00-09:30 Susanna Louhimies, The European Commission, BE-Brussels
Directive 2010/63/EU: Overview of the work of Commission Expert Working Groups on an EU Framework for Education and Training and on Project Evaluation

09:30-10:00 Katharina Kluge, Federal Ministry of Food, Agriculture and Consumer Protection, DE-Bonn
Implementation of Directive 2010/63/EU into German law

10:00-10:15 Ursula G. Sauer, Scientific Consultancy – Animal Welfare, DE-Neubiberg
Ethical review of projects involving non-human primates funded under the European Union’s 7th Research Framework Programme

10:15-10:30 Norbert Alzmann, Messerli Research Institute, AT-Vienna
A catalogue of criteria to objectify the harm-benefit analysis according to Austrian legislation

10:30-10:45 Marie-Jeanne Schiffelers, Utrecht University School of Governance, NL-Utrecht
Factors influencing regulatory acceptance and use of 3R models & strategies to improve this process: The case of the EOGRTS

10:45-11:00 Mangala Gunatilake, University of Colombo, LK-Colombo
Steps taken to implement 3Rs concept in research using animals in Sri Lanka

11:00-11:40 Coffee break, posters and exhibition

Session V – Consequences of the 2013 EU Marketing Ban for Cosmetics & NanoTox

Chairs: Dagmar Jirova (CZ) & Klaus Schröder (AT)

11:40-11:55 Gamze Ates, Vrije Universiteit Brussel, BE-Brussels
Retrospective analysis of the mutagenicity/genotoxicity data of the cosmetic ingredients present on the Annexes of the Cosmetic EU legislation

11:55-12:10 Helena Kandarova, MatTek In Vitro Life Science Laboratories, SK-Bratislava
Ability of the reconstructed human tissue models to correctly predict phototoxicity and photopotency of topically applied substances and formulations: Review of available data

12:10-12:25 Martin Paparella, Environment Agency Austria, AT-Vienna
Uncertainty of testing methods – What do we (want to) know?

12:25-12:40 Katy Taylor, BUAV/ECEAE, UK-London
The ADAPT principles for regulatory authorities

12:40-12:55 Stefanie Schindler, Animalfree Research, CH-Bern
Mind the gap – developing and implementing integrated testing strategies into nanotoxicology

12:55-13:10 Cornelia Loos, University of Ulm, DE-Ulm
The chick chorioallantoic membrane (CAM) assay as a model for the development of antitumor nanotherapeutics

13:10-14:30 Lunchtime poster session – poster session II
(business lunch to be served at the congress venue)
Chairs: Helena Kandarova (SK) & Ursula Sauer (DE)

Session VI – Specific Endpoints of Toxicity – Session I (part I)

Chairs: Rodger Curren (US) & Robert Landsiedel (DE)

14:30-14:50 Robert Landsiedel, BASF SE, DE-Ludwigshafen
Hurdles during the development and application of alternative methods: a perspective from the chemical industry

14:50-15:05 Judith Madden, Liverpool John Moores University, UK-Liverpool
Modelling local and systemic toxicity: Incorporation of in silico predictions in the development of adverse outcome pathways

15:05-15:20 Jan Willem Van der Laan, Medicines Evaluation Board, NL-Utrecht
Pharmacology and Carcinogenicity. Predicitivity as a possibility to reduce the number of carcinogenicity studies

15:20-15:35 Katherina Sewald, Fraunhofer ITEM, DE-Hannover
Pre-validation of the ex vivo model PCLS for the prediction of acute inhalation toxicity

15:35-15:50 Rodger Curren, Institute for In Vitro Sciences Inc. (IIVS), US-Gaithersburg, MD
Further refinement of the Reconstructed Skin Micronucleus Genotoxicity Assay (RSMN)

15:50-16:05 TzuTzuy Ramirez Hernandez, BASF SE, DE-Ludwigshafen
Inter-laboratory validation of the Yeast Estrogen and Yeast Androgen Screens for identification of Endocrine Active Substances

16:05-16:45 Coffee break, posters and exhibition

Session VII – Tox21 (TT21C) & Specific Endpoints of Toxicity (part II)

Chairs: Carole Mathis (CH) & Roman Kolar (DE)

16:45-17:00 Robert A Coleman, Safer Medicines Trust, UK-London
Humanizing toxicity testing in the 21st century: Who should be responsible for introduction of human biology-based tests into regulatory process?

17:00-17:15 Carl Westmoreland, Unilever, UK-Bedford
21st century safety science and non animal approaches at Unilever

17:15-17:30 Marcel Leist, Univ. of Konstanz, DE-Konstanz
Use of transcriptome profiling in stem cell based test systems for reproductive toxicity

17:30-17:45 Julia Hoeng, Philip Morris International, CH- Neuchâtel
Assessing the effects of repeated cigarette smoke exposure using human organotypic systems reproducing the respiratory tract in vitro

17:45-18:00 Anne Krug, Univ. of Konstanz, DE-Konstanz
Integrating transcriptomics and metabolomics to identify pathways of toxicity of the parkinsonian toxin MPP+

18:30 Departure for the social evening

19:00 Social evening

Wednesday, 18.09.2013

Session VIII – Implementing Alternatives into Basic Research

Chairs:Tzutzuy Ramirez-Hernandez (DE) & Tuula Heinonen (SF)

09:00-09:15 Gerhard Püschel, University of Potsdam, DE-Potsdam
Cell culture-based in vitro method for determining the activity of the botulinum toxin

09:15-09:30 Karin Schütze, CellTool GmbH, DE-Bernried
Novel laser-based identification of cancer cells and monitoring of cell-agent interactions

09:30-09:45 Theresia Licka, University of Veterinary Medicine, AT-Vienna
Research in perfused limbs successfully replaces induction of laminitis in live horses

09:45-10:00 Günther Weindl, Freie Universität Berlin, DE-Berlin
Phase I biotransformation of testosterone by human skin and reconstructed skin tissues

10:00-10:15 Candida Nastrucci, Tor Vergata University, IT-Rome
The alternatives to animal experiments in basic research and education: Status and possibilities in the EU

10:15-10:30 Johannes Grillari, VIBT – BOKU, AT-Vienna
Immortalized primary-like human cells as novel model systems in nephrotoxicity

10:30-11:00 Coffee break, posters and exhibition

Session IX – Drugs, Vaccines & EU FP7 Projects

Chairs: Horst Spielmann (DE) & Eleonore Haltner-Ukomadu (DE)

11:00-11:18 Maren Bernau, Livestock Center Oberschleissheim, DE- Oberschleissheim
Magnetic resonance imaging as an alternative method in safety-testing of veterinary vaccines – preliminary results in pigs

11:18-11:36 Otmar Schmid, Comprehensive Pneumology Center & Helmholtz Zentrum München, DE-Neuherberg
New perspectives for realistic and efficient in vitro screening for inhalable drugs

11:36-11:54 Jiu Jia, Department of Clinical Pharmacology, University Medicine, Greifswald, Germany
Use of in vitro cell assays and noninvasive imaging techniques to reduce animal experiments in drug development

11:54-12:12 Francois Busquet, CAAT EU, BE-Brussels
The CAAT EU policy program in Brussels

12:12-12:30 Sunniva Förster, University of Konstanz, DE-Konstanz
Development and application of an algorithm to determine statistically-valid non-cytotoxic concentrations from imperfect in vitro cytotoxicity data sets

12:30-12:40 Closing remarks

12:40 End of the 18th European Congress on Alternatives to Animal Testing

13:00 Start of the post congress EUSAAT 2013 Training Course